EBS Q1 2025 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$222M-26.0% YoY

Gross Profit

$119M53.7% margin

Operating Income

$50M22.5% margin

Net Income

$68M30.6% margin

EPS (Diluted)

$1.19

QoQ Revenue Growth

+14.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$873M

Stockholders' Equity

$553M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$222M	$300M	-26.0%
Gross Profit	$119M	$141M	-15.2%
Operating Income	$50M	$40M	+25.4%
Net Income	$68M	$9M	+655.6%

Revenue Segments

Product

$209M94%

Contracts and Grants

$13M6%